Actinobacillus actinomycetemcomitans lipopolysaccharide-mediated experimental bone loss model for aggressive periodontitis.

Actinobacillus actinomycetemcomitans lipopolysaccharide-mediated experimental bone loss model for aggressive periodontitis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Actinobacillus actinomycetemcomitans lipopolysaccharide-mediated experimental bone loss model for aggressive periodontitis. Abstract Text:

Jill E Rogers,Fei Li,Derek D Coatney,Carlos Rossa,Paul Bronson,Jaclynn M Krieder,William V Giannobile,Keith L Kirkwood,

BACKGROUND: Bacterial constituents, such as Gram-negative derived lipopolysaccharide (LPS), can initiate inflammatory bone loss through induction of host-derived inflammatory cytokines. The aim of this study was to establish a model of aggressive inflammatory alveolar bone loss in rats using LPS derived from the periodontal pathogen Actinobacillus actinomycetemcomitans. METHODS: Eighteen female Sprague-Dawley rats were divided into LPS test (N = 12) and saline control (N = 6) groups. All animals received injections to the palatal molar gingiva three times per week for 8 weeks. At 8 weeks, linear and volumetric alveolar bone loss was measured by micro-computed tomography (microCT). The prevalence of inflammatory infiltrate, proinflammatory cytokines, and osteoclasts was assessed from hematoxylin and eosin, immunohistochemical, or tartrate-resistant acid phosphatase (TRAP)-stained sections. Statistical analysis was performed. RESULTS: A. actinomycetemcomitans LPS induced severe bone loss over 8 weeks, whereas control groups were unchanged. Linear and volumetric analysis of maxillae by microCT indicated significant loss of bone with LPS administration. Histologic examination revealed increased inflammatory infiltrate, significantly increased immunostaining for interleukin IL-6 and -1beta and tumor necrosis factor-alpha, and more TRAP-positive osteoclasts in the LPS group compared to controls. CONCLUSION: Oral injections of LPS derived from the periodontal pathogen A. actinomycetemcomitans can induce severe alveolar bone loss and proinflammatory cytokine production in rats by 8 weeks.

Actinobacillus actinomycetemcomitans lipopolysaccharide-mediated experimental bone loss model for aggressive periodontitis. Publishing Authors By Initials

JE Rogers,F Li,DD Coatney,C Rossa,P Bronson,JM Krieder,WV Giannobile,KL Kirkwood,

For similar peptides: intercellular signaling peptides and proteins: cytokines: monokines: tumor necrosis factor-alpha research abstracts see: peptides: intercellular signaling peptides and proteins: cytokines: monokines: tumor necrosis factor-alpha research

PUBMED ID PMID:

MEDLINE DATE:

Actinobacillus actinomycetemcomitans lipopolysaccharide-mediated experimental bone loss model for aggressive periodontitis. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: Journal of periodontology

VOLUME: 78

Page Numbers: 550-8

Journal Abbreviation: J. Periodontol.

ISSN: 0022-3492

DAY: 3

MONTH: Mar

YEAR: 2007

Actinobacillus actinomycetemcomitans lipopolysaccharide-mediated experimental bone loss model for aggressive periodontitis. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8000345

Actinobacillus actinomycetemcomitans lipopolysaccharide-mediated experimental bone loss model for aggressive periodontitis. Keywords Mesh Terms:

KEYWORDS: Tumor Necrosis Factor-alpha

MESH TERMS: biosynthesis

Chemical & Substance for Abstract: Actinobacillus actinomycetemcomitans lipopolysaccharide-mediated experimental bone loss model for aggressive periodontitis. Information

Substance Name: Tumor Necrosis Factor-alpha

Registry Number: 0

Grant and Affiliation Information for Actinobacillus actinomycetemcomitans lipopolysaccharide-mediated experimental bone loss model for aggressive periodontitis.

AFFILIATION: Department of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, MI 48109-1078, USA.

Country: United States

AGENCY: United States NIAMS

GRANT: P30-AR46024

ACRONYM: AR

MEDLINETA: J Periodontol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Actinobacillus actinomycetemcomitans lipopolysaccharide-mediated experimental bone loss model for aggressive periodontitis Related Publications

• A comparison of computerized and pencil-and-paper tasks in assessing cognitive function in community-dwelling older people in the Newcastle 85+ Pilot Study.
• A dominant function of p38 mitogen-activated protein kinase signaling in receptor activator of nuclear factor-kappaB ligand expression and osteoclastogenesis induction by Aggregatibacter actinomycetemcomitans and Escherichia coli lipopolysaccharide.
• A systematic look at an old problem.
• Actinobacillus actinomycetemcomitans lipopolysaccharide-mediated experimental bone loss model for aggressive periodontitis.
• Developing indications for the use of sentinel lymph node biopsy and adjuvant high-dose interferon alfa-2b in melanoma.
• Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents.
• Informed consent in Ghana: what do participants really understand?
• Is there any monitoring of the quality of vitamin A capsules used in supplementation programs?
• Management of metastatic melanoma.
• Medical challenges of improving the quality of a longer life.
• Medicine a century ago.
• Melanoma: immunotherapeutic approaches.
• Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.
• NIMS and ICS: from compliance to competence.
• New experimental model for the primary evaluation of topical contra-inflammatory agents.
• Patterns of postural deformity in non-ambulant people with cerebral palsy: what is the relationship between the direction of scoliosis, direction of pelvic obliquity, direction of windswept hip deformity and side of hip dislocation?
• Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion.
• Present role and future potential of type I interferons in adjuvant therapy of high-risk operable melanoma.
• Problems in the standardization of Factor VIII assays.
• Recurrent corneal erosion: characteristics and management options.
• Testing evolutionary theories of menopause.
• The forces between protein molecules in solution: a summary.
• The frequency response of frog muscle spindles under various conditions.
• Thymic cyst of the neck.
• Trade-off mediated effects on the genetics of human survival caused by increasingly benign living conditions.
• Transcriptional activation of MMP-13 by periodontal pathogenic LPS requires p38 MAP kinase.
• Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer.
• Understanding ageing from an evolutionary perspective.
• p38 MAPK signaling in oral-related diseases.
• p38{alpha} Stabilizes Interleukin-6 mRNA via Multiple AU-rich Elements.